0.40Open0.40Pre Close0 Volume81 Open Interest16.00Strike Price0.00Turnover176.46%IV64.00%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.1986Delta0.0636Gamma25.00Leverage Ratio-0.0273Theta0.0010Rho4.96Eff Leverage0.0069Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet